1 조영선, "특허소송에 있어서 발명의 진보성 판단의 국제기준에 관한 비교분석" 법원행정처 97-98, 2010
2 "특허법원 2005. 11. 3. 선고 2004허6521 판결"
3 "특허법원 2005. 11. 3. 선고 2004허6521 판결"
4 특허청, "특허ㆍ실용신안 심사지침서"
5 특허청, "특허ㆍ실용신안 심사지침서"
6 특허청, "특허 ․ 실용신안 심사지침서"
7 "지침서"
8 정윤택, "제약분야의 에버그리닝(Evergreening)특허전략과 FTA 연구" 한국지식재산연구원 6 (6): 147-189, 2011
9 박정희, "선택발명의 신규성을 부정하기 위한 요건 등" 법원행정처 514-517, 2010
10 김운호, "선택발명의 명세서 기재요건" 법원행정처 145-146, 2007
11 강기중, "선택발명에서의 진보성 판단방법" 법원행정처 2004
12 특허청, "선진 특허법제 구축을 위한 특허법체계 전면 개편방안 연구" 76-, 2010
13 특허청, "산업부문별 심사실무 가이드, 의약ㆍ화장품분야"
14 특허청, "산업부문별 심사실무 가이드, 유ㆍ무기 화합물 및 세라믹스 분야"
15 특허청, "산업부문별 심사실무 가이드, 유ㆍ무기 화합물 및 세라믹스 분야"
16 특허청, "산업부문별 심사실무 가이드, 유ㆍ무기 화합물 및 세라믹스 분야"
17 특허청, "산업부문별 심사실무 가이드, 생명공학분야"
18 특허청, "산업부문별 심사실무 가이드, 생명공학분야"
19 "대법원 2011.7.14. 선고 2010후2865 판결"
20 "대법원 2011. 7. 14. 선고 2010후2872 판결"
21 "대법원 2011. 7. 14. 선고 2010후2865 판결"
22 "대법원 2010. 3. 5. 선고 2008후3469, 3476 판결"
23 "대법원 2010. 3. 25. 선고 2008후3469, 3476 판결"
24 "대법원 2009. 10. 15. 선고 2008후736,743 판결"
25 "대법원 2009. 10. 15. 선고 2008후736, 743 판결"
26 "대법원 2003. 4. 25. 선고 2001후2740 판결"
27 "대법원 2003. 10. 24. 선고 2002후1935 판결"
28 "대법원 2002. 12. 26. 선고 2001후 2375 판결"
29 "대법원 2001. 11. 30. 선고 2001후65 판결"
30 "知財高裁 平19年 7. 19. 平18(行ケ) 10487号"
31 "知財高裁 平18年 2. 16. 平17(行ケ) 10205号"
32 "知財高裁 平18年 10. 30. 平17(行ケ) 10820号"
33 "知財高裁 平17年 10. 19. 平17(行ケ)10013号"
34 中山信弘, "特許法注解(第3版)" 靑林書院 635-639, 2011
35 潮海久雄, "特許法において開示要件(實施可能要件ㆍサポート要件)が果たす役割" 16 : 131-, 2007
36 "東京高裁 平16年 10. 6. 平15(行ケ)467号"
37 "東京高裁 平14年 11. 28. 平13(行ケ)334号"
38 "東京高裁 平10年 10. 30. 平8(行ケ) 201号"
39 日本特許廳, "工業所有權法(産業財産權法)逐條解說[第18版]" 發明協會 117-118, 2010
40 "http://www.managingip.com/Article/2324828/India-Novartis-fights-on-in-Gleevec-battle.html"
41 "http://www.ftc.gov/os/2003/10/innovationrpt.pdf"
42 Christopher M. Holman, "Unpredictability in Patent Law and Its Effect on Pharmaceutical Innovation" 76 : 2011
43 Shamnad Basheer, "The ‘Efficacy’ of Indian Patent Law : Ironing out the Creases in Section 3(d)" 5 (5): 238-, 2008
44 Rebecca S. Eisenberg, "The Role of the FTA in Innovation Policy" 13 : 354-356, 2007
45 Dan L. Burk, "The Patent Crisis and How the Courts Can Solve It" The Univ. of Chicago Press 22-26, 2009
46 Lucille J. Brown, "The Markush Challenge" 31 (31): 2-, 1991
47 John M. Olin, "The Disclosure Function of the Patent System(or Lack Thereof)" 118 (118): 2025-2026, 2005
48 N.S. Gopalakrishnan, "TRIPS flexibilities : the case of India, Intellectual Property and Access to Medicines : Papers and Perspectives"
49 "T182/89 Sumitomo"
50 "T1191/01 Seven Transmembrane Recoptor"
51 Timothy R. Holbrook, "Possession in Patent Law" 59 (59): 123-158, 2006
52 Bengt Domeij, "Pharmaceutical Patents in Europe" Kluwer Law International 25-26, 2000
53 Carl Shapiro, "Patent System Reform : Economic Analysis and Critique" 19 : 1028-1033, 2004
54 Janice M. Mueller, "Patent Law(3rd. Edit.)" Wolters Kluwer 2009
55 "Nelson v. Bowler, 626 F2d.853, 856, 206 USPQ 881, 883(CCPA 1980)"
56 "MPEP 2107. 03.Ⅲ,Ⅳ"
57 "MPEP 2107. 03.Ⅱ"
58 "MPEP 2107. 03.Ⅰ"
59 "MPEP 2107. 01.Ⅰ"
60 "MPEP 2107 Ⅱ.(B)(2)"
61 "Janssen Pharmaceutica N. V. v. Teva Pharmaceuticals USA, Inc., 583 F.3d 1317(Fed. Cir. 2009)"
62 Aron S. Kesselheim, "Intellectual Property Policy in the Pharmaceutical Science : The Effect of Inappropriate Patents and Market Exclusivity Extensions on the Health Care System" 9 (9): 307-309, 2007
63 "In re Zenitz 333 F.2d 924, 142 U.S.P.Q. (BNA) 158(C.C.P.A. 1964)"
64 "In re Wright, 999 F.2d 1557, 1561~62(Fed. Cir. 1993)"
65 "In re Saunders 444 F.2d 599, 170 U.S.P.Q. (BNA) 213(C.C.P.A. 1971)"
66 "In re Marzocchi, 439 F.2d 220, 223(CCPA. 1971)"
67 "In re Fouche, 439 F.2d 1237, 1243(CCPA. 1971)"
68 "In re Brana 51 F.3d 1560(Fed. Cir. 1995)"
69 Sean B. Seymore, "Heightened Enablement in the Unpredictable Arts" 59 : 154-157, 2008
70 Carlos M. Correa, "Excerpts from guidelines for the examination of pharmaceutical patents, Intellectual Property and Access to Medicines : Papers and Perspective"
71 Michelle L. Evans, "Establishing Lack of Utility Under 35 U.S.C.A. §101"
72 "Eli Lilly and Co. v. Actavis Elizabeth LLC., Fed. Cir. No. 2010-1500. July 29"
73 "Eli Lilly and Co. v. Actavis Elizabeth LLC., Fed. Cir. No. 2010-1500. July 29"
74 "Eli Lilly and Co. v. Actavis Elizabeth LLC., 731 F.Supp. 2d 348, 352(D.N.J. 2010)"
75 "Eli Lilly Canada Inc. et al. v. Novopharm Ltd., 2011 FC 1288"
76 "EPO Guidelines, 2011, Part C. ChapterⅡ. 4.1"
77 "EPO Guidelines, 2011, Chapter C. Ⅳ. 5.3.5"
78 "EPO Guidelines"
79 "EPC Rule 23e(3)"
80 Lisa Larrimore Ouellette, "Do Patents Disclose Useful Information?" 25 : 532-547, 2012
81 Richard Hacon, "Concise European Patent Law" Kluwer Law International 2007
82 Irah H. Donner, "Combating Obviousness Rejections Under 35 U.S.C. section 103" 6 : 217-218, 1996
83 "Burroughs Wellcome Co. v. Barr Lab., Inc., 40 F.3d 1223, 1227-28(Fed. Cir. 1994)"
84 "Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1205, 18 USPQ 2d. 1016, 1020"
85 Jochen E. BÜHLING, "AIPPI summary report Question 209 Selection inventions–The Inventive Step Requirement, Other Patentability Criteria and Scope of Protection"
86 "35 U.S.C. §101"